ATC Group: R03AL06 Olodaterol and tiotropium bromide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R03AL06 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R03 Drugs for obstructive airway diseases
3 R03A Adrenergics, inhalants
4 R03AL Adrenergics in combination with anticholinergics
5 R03AL06 Olodaterol and tiotropium bromide

Active ingredients in R03AL06

Active Ingredient Description
Olodaterol and Tiotropium bromide

Fixed dose combination containing a long acting muscarinic receptor antagonist, tiotropium and a long acting beta2-adrenergic agonist, olodaterol (LAMA/LABA). The two active ingredients provide additive bronchodilation due to their different mode of action. Since muscarinic receptors appear to be more prominent in the central airways while β2 adrenoceptors have a higher expression level in the peripheral airways, a combination of tiotropium and olodaterol should provide optimal bronchodilatation in all regions of the lungs.

Related product monographs

Title Information Source Document Type  
SPIOLTO RESPIMAT Inhalation solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Malta (MT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

Spain (ES)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.